Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy.

Molecular therapy : the journal of the American Society of Gene Therapy - 1 Aug 2007

Almarza Elena, Río Paula, Meza Nestor W, Aldea Montserrat, Agirre Xabier, Guenechea Guillermo, Segovia José C, Bueren Juan A

Abstract excerpt

Recent published data have shown the efficacy of gene therapy treatments of certain monogenic diseases. Risks of insertional oncogenesis, however, indicate the necessity of developing new vectors with weaker or cell-restricted promoters to minimize the trans-activation activity of integrated prov...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Methylation
Share to Fanconi Anemia Complementation Group A Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Transfer Techniques

Share to Genetic Therapy

Share to Genetic Vectors

Share to Lentivirus

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-vav

Source

Identifiers

PMID: 17534266
DOI: 10.1038/sj.mt.6300213

Genes

FANCA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17534266-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy.PMID 17534266Read ↗

Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia.Semantic proximity Read ↗

Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors.Semantic proximity Read ↗

Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector.Semantic proximity Read ↗

High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectorsSemantic proximity Read ↗

Retroviral gene transfer for the assignment of Fanconi anemia (FA) patients to a FA complementation group.Semantic proximity Read ↗

Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector.Semantic proximity Read ↗

Functional correction of Fanconi anemia group A hematopoietic cells by retroviral gene transfer.Semantic proximity Read ↗

A Rapid and Quantitative Assay for Measuring Neighboring Gene Activation by Vector ProvirusesSemantic proximity Read ↗

Regulation of the vav proto-oncogene by LKLF.Semantic proximity Read ↗

Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice.Semantic proximity Read ↗

The Fanconi anemia complementation group C gene (FAC) suppresses transformation of mutant fibroblasts by the SV40 virus.Semantic proximity Read ↗

PU.1 regulates the expression of the vav proto-oncogene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.